
Opinion|Videos|January 15, 2025
Sequencing Therapies in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.
Advertisement
Episodes in this series

- Please give an overview of 2L treatment strategies.
- If patients are refractory to the available 1L options, how would you choose a 2L treatment?
- Please give a brief overview of recent updates from IMerge (Santini et al, EHA 2024; Zeidan et al, JCO 2024).
- In your opinion, and considering NCCN Guidelines MDS-5, where do you see imetelstat in the treatment sequencing for LR-MDS?
- What can we learn from these studies and are there any remaining knowledge gaps to note?
Advertisement
Related to this article

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
3
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5

